In this article, we will discuss the 11 Most Active Small Cap Stocks to Buy.
Investing in small-cap stocks that are active in terms of average trading volume offers a balanced approach to capturing growth while managing some of the inherent risks associated with smaller companies. Small caps are widely known for their ability to deliver outsized returns, as they typically operate earlier in their growth cycle with greater room for revenue and earnings expansion. However, they are also often associated with lower liquidity and higher volatility—challenges that can be meaningfully reduced by focusing on those with consistently high trading volume.
A high three-month average volume is a strong indicator of sustained market participation, ensuring that investors can enter and exit positions efficiently without significantly impacting the stock price. This improved liquidity leads to narrower bid-ask spreads and reduces execution risk, making it easier to transact at fair market value. While small-cap stocks remain more volatile than large-cap peers, higher trading volume helps stabilize price movements by minimizing the impact of isolated large trades.
Importantly, elevated trading volume can also signal growing institutional interest. Since small-cap stocks tend to have limited analyst coverage, increased activity from hedge funds and mutual funds may indicate that the market is beginning to recognize the company’s underlying value. When accompanied by upward price momentum, this can validate the strength of a trend and suggest the potential for a broader re-rating.
At the same time, small-cap companies offer unique growth advantages. Their agility allows them to adapt quickly to emerging technologies and niche opportunities, and they are often attractive acquisition targets for larger firms, which can result in significant shareholder premiums.
By focusing on small-cap stocks with strong trading volume, investors can pursue high-growth opportunities while benefiting from better liquidity, improved price discovery, and more reliable market signals—creating a more disciplined and risk-aware approach to small-cap investing.
With this context in mind, here is a list of the 11 most active small cap stocks to buy.
Our Methodology
We used Yahoo Finance’s “most active stocks” screen to identify stocks with a high 3-month average volume, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. Of these, we picked out small-cap stocks for this article, with market capitalization between $300 million and $2 billion. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
11 Most Active Small Cap Stocks to Buy
11. NextDecade Corporation (NASDAQ:NEXT)
3-month Average Volume: 3.11 million
On March 5, TD Cowen lowered its price target on NextDecade Corporation (NASDAQ:NEXT) to $6 from $7 while maintaining a Hold rating, reflecting updated assumptions around LNG pricing and project economics. The firm noted that while realized margins may be lower than previously expected, the company’s ability to increase contracted capacity and utilize project-level financing provides a constructive pathway forward.
Previously, on February 24, Morgan Stanley reduced its price target on NextDecade Corporation (NASDAQ:NEXT) to $7 from $10 and maintained an Equal Weight rating, citing expectations for a potential oversupply in the global LNG market. While near-term catalysts remain limited as projects are still under development, the long-term structural demand for LNG continues to underpin the investment thesis.
NextDecade Corporation (NASDAQ:NEXT) is a developer of liquefied natural gas export infrastructure, focused on large-scale projects along the U.S. Gulf Coast. Despite near-term uncertainty, the company’s strategic positioning within the global LNG supply chain and its progress toward project execution provide meaningful long-term upside as energy demand continues to evolve.
10. CytomX Therapeutics, Inc. (NASDAQ:CTMX)
3-month Average Volume: 5.91 million
On March 18, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw Jefferies raise its price target to $16 from $8 while maintaining a Buy rating following encouraging Phase 1 data for its lead asset Varseta-M in late-line metastatic colorectal cancer. The analyst highlighted the therapy’s potential as a differentiated antibody-drug conjugate (ADC), estimating a commercial opportunity exceeding $1 billion in later-line settings, with significantly larger upside as the drug advances into earlier treatment lines.
The same day, Guggenheim also raised its price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $15 from $10, reiterating a Buy rating. The firm noted that updated clinical data at both tested dose levels materially outperformed current standards of care, prompting an increase in its estimated probability of success to 60% from 30%. This meaningful improvement in clinical confidence, combined with strong efficacy signals, reinforces the asset’s potential to become a best-in-class therapy.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical-stage oncology-focused biopharmaceutical company developing conditionally activated PROBODY® therapeutics designed to target tumors while limiting systemic toxicity. With increasingly compelling clinical data and rising analyst conviction, the company appears well-positioned to unlock significant value as its pipeline advances, supporting a favorable risk-reward profile for investors seeking exposure to innovative oncology assets.
